Medopal
Brand names,
Medopal
Analogs
Medopal
Brand Names Mixture
Medopal
Chemical_Formula
C56H71N9O23S
Medopal
RX_link
http://www.rxlist.com/cgi/generic4/mycamine.htm
Medopal
fda sheet
Medopal
msds (material safety sheet)
Medopal
Synthesis Reference
No information avaliable
Medopal
Molecular Weight
1270.28 g/mol
Medopal
Melting Point
No information avaliable
Medopal
H2O Solubility
Freely soluble as sodium salt (> 200mg/mL)
Medopal
State
Solid
Medopal
LogP
No information avaliable
Medopal
Dosage Forms
Powder for solution (for injection)
Medopal
Indication
For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Medopal
Pharmacology
Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
Medopal
Absorption
No information avaliable
Medopal
side effects and Toxicity
Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
Medopal
Patient Information
No information avaliable
Medopal
Organisms Affected
Aspergillis, Candida and other fungi